Shobna Sawry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shobna Sawry has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
- Jean Le Roux
Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
9 shared publications - Lee Fairlie
Wits RHI, University of the Witwatersrand, Johannesburg, South Africa
8 shared publications - Faeezah Patel
Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5 shared publications - Helen Rees
Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5 shared publications - Mrinmayee Dhar
Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 shared publications - Alex Sigal
Africa Health Research Institute and University of KwaZulu-Natal, Durban, South Africa
3 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e102863
Mobile Heat Early Warning System for Pregnant and Postpartum Women in South Africa: Prospective Observational Evaluation Study
Background: Early warning systems (EWS) have the potential to reduce heat-related health risks, yet few are designed specifically for vulnerable populations. Pregnant women and infants, often cared for by postpartum women, are particularly susceptible to heat-related illnesses. The MotherHeat Alert mobile app is a heat EWS specifically developed for pregnant and postpartum women. Objective: This study aimed to assess the usability and effectiveness of the MotherHeat Alert in the Tshwane District, South Africa. Methods: This prospective observational evaluation study included a cohort of 201 participants (100 pregnant and 101 postpartum) who were followed over a 6-month period. In addition, a questionnaire was administered at 3 time points (baseline, midpoint, and end point) to collect self-reported information on health, living situation, and heat exposure, among other parameters. Usability was evaluated in the end point questionnaire through a validated Post-Study System Usability Questionnaire (PSSUQ), using descriptive statistics. Effectiveness was assessed through changes in self-reported heat-protective behaviors between baseline, midpoint, and end point, as well as through end point assessments of heat-health knowledge increase and self-reported behavior change attributable to the intervention. Generalized estimating equations were used to analyze repeated measures of heat-protective behaviors, while descriptive statistics were used to summarize end point–reported knowledge gains and behavior change. Results: Usability scores indicated high overall usability, with mean PSSUQ scores of 1.76 (SD 0.60) among pregnant women and 1.37 (SD 0.45) among postpartum women. Similar patterns were observed across most PSSUQ subscales, including system usefulness, interface quality, and information quality. Most self-reported behavior change due to alerts received through the app was rated as large to very large by the pregnant women (47/70, 67%) and postpartum women (68/82, 83%). Nevertheless, comparing behavior change at baseline and end point mainly highlighted a decrease in protective behavior in both pregnant and postpartum cohorts. Self-reported knowledge increase among pregnant and postpartum women was reported as large to very large following the use of the EWS (55/70, 79% and 72/82, 88%, respectively). Importantly, however, attrition was substantial, particularly among pregnant participants, reaching 30% (30/100) in the pregnant cohort and 19% (19/101) in the postpartum cohort by end point. Conclusions: The MotherHeat Alert app demonstrated positive outcomes in usability. Effectiveness showed conflicting results, with positive self-reports on behavior change and knowledge increase, yet a decrease in protective heat behaviors when comparing baseline and midpoint with end point results, likely due to seasonality effects. Nevertheless, these findings highlight the potential of tailored EWS to support heat adaptation among pregnant and postpartum populations. Successful implementation and scalability require careful consideration of contextual factors, further assessment of long-term usability and integration into existing health infrastructure.
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e102863
Open AccessMobile Heat Early Warning System for Pregnant and Postpartum Women in South Africa: Prospective Observational Evaluation Study
Background: Early warning systems (EWS) have the potential to reduce heat-related health risks, yet few are designed specifically for vulnerable populations. Pregnant women and infants, often cared for by postpartum women, are particularly susceptible to heat-related illnesses. The MotherHeat Alert mobile app is a heat EWS specifically developed for pregnant and postpartum women. Objective: This study aimed to assess the usability and effectiveness of the MotherHeat Alert in the Tshwane District, South Africa. Methods: This prospective observational evaluation study included a cohort of 201 participants (100 pregnant and 101 postpartum) who were followed over a 6-month period. In addition, a questionnaire was administered at 3 time points (baseline, midpoint, and end point) to collect self-reported information on health, living situation, and heat exposure, among other parameters. Usability was evaluated in the end point questionnaire through a validated Post-Study System Usability Questionnaire (PSSUQ), using descriptive statistics. Effectiveness was assessed through changes in self-reported heat-protective behaviors between baseline, midpoint, and end point, as well as through end point assessments of heat-health knowledge increase and self-reported behavior change attributable to the intervention. Generalized estimating equations were used to analyze repeated measures of heat-protective behaviors, while descriptive statistics were used to summarize end point–reported knowledge gains and behavior change. Results: Usability scores indicated high overall usability, with mean PSSUQ scores of 1.76 (SD 0.60) among pregnant women and 1.37 (SD 0.45) among postpartum women. Similar patterns were observed across most PSSUQ subscales, including system usefulness, interface quality, and information quality. Most self-reported behavior change due to alerts received through the app was rated as large to very large by the pregnant women (47/70, 67%) and postpartum women (68/82, 83%). Nevertheless, comparing behavior change at baseline and end point mainly highlighted a decrease in protective behavior in both pregnant and postpartum cohorts. Self-reported knowledge increase among pregnant and postpartum women was reported as large to very large following the use of the EWS (55/70, 79% and 72/82, 88%, respectively). Importantly, however, attrition was substantial, particularly among pregnant participants, reaching 30% (30/100) in the pregnant cohort and 19% (19/101) in the postpartum cohort by end point. Conclusions: The MotherHeat Alert app demonstrated positive outcomes in usability. Effectiveness showed conflicting results, with positive self-reports on behavior change and knowledge increase, yet a decrease in protective heat behaviors when comparing baseline and midpoint with end point results, likely due to seasonality effects. Nevertheless, these findings highlight the potential of tailored EWS to support heat adaptation among pregnant and postpartum populations. Successful implementation and scalability require careful consideration of contextual factors, further assessment of long-term usability and integration into existing health infrastructure.
- Open Access
- 29 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
A Mobile Heat Early Warning System for Pregnant and Postpartum Women in South Africa: An Evaluation of Usability and Effectiveness (Preprint)
BACKGROUND Early Warning Systems (EWS) have the potential to reduce heat-related health risks, yet few are designed specifically for vulnerable populations. Pregnant women and infants, often cared for by postpartum women, are particularly susceptible to heat-related illnesses. The MotherHeat Alert mobile application is a heat EWS specifically developed for pregnant and postpartum women. Objective: In this study we aimed to assess the usability and effectiveness of the MotherHeat Alert in the Tshwane District, South Africa. OBJECTIVE In this study we aimed to assess the usability and effectiveness of the MotherHeat Alert in the Tshwane District, South Africa. METHODS This prospective observational evaluation study included a cohort of 201 participants (100 pregnant, 101 postpartum) which were followed over a six-month period. In addition, a questionnaire was administered at three time points; baseline, midline and endline, to collect self-reported information on health, living situation, heat exposure, amongst other parameters. Usability was evaluated in the endline questionnaire through a validated Post-Study System Usability Questionnaire (PSSUQ), using descriptive statistics. Effectiveness was assessed through changes in self-reported heat-protective behaviours between baseline, midline and endline, as well as through endline assessments of heat-health knowledge increase and self-reported behaviour change attributable to the intervention. Generalised estimating equations were used to analyse repeated measures of heat-protective behaviours, while descriptive statistics were used to summarise endline-reported knowledge gains and behaviour change. RESULTS Usability scores indicated high overall usability, with mean PSSUQ scores of 1.76 (SD=0.60) among pregnant women and 1.37 (SD=0.45) among postpartum women. Similar patterns were observed across most PSSUQ subscales, including system usefulness, interface quality and information quality. Most self-reported behaviour change due to alerts received through the app was rated as large to very large by the pregnant women (67.2%) and postpartum women (82.9%). Nevertheless, comparing behaviour change at baseline and endline mainly highlighted a decrease in protective behaviour in both pregnant and postpartum cohorts. Self-reported knowledge increase among pregnant and postpartum women was reported as large to very large following the use of the EWS (79% and 88%, respectively). CONCLUSIONS The MotherHeat Alert application demonstrated positive outcomes in usability. Effectiveness showed conflicting results, with positive self-reports on behaviour change and knowledge increase, yet a decrease in protective heat behaviours when comparing baseline and midline with endline results, likely due to seasonality effects. Nevertheless, these findings highlight the potential of tailored EWS to support heat adaptation among pregnant and postpartum populations. Successful implementation and scalability require careful consideration of contextual factors, further assessment of long-term usability and integration into existing health infrastructure. CLINICALTRIAL The study was registered with the South African National Clinical Trial Registry (DOH-27-032025-5623), as part of the EU and UK-funded High Horizons project.
- 29 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Mobile Heat Early Warning System for Pregnant and Postpartum Women in South Africa: An Evaluation of Usability and Effectiveness (Preprint)
BACKGROUND Early Warning Systems (EWS) have the potential to reduce heat-related health risks, yet few are designed specifically for vulnerable populations. Pregnant women and infants, often cared for by postpartum women, are particularly susceptible to heat-related illnesses. The MotherHeat Alert mobile application is a heat EWS specifically developed for pregnant and postpartum women. Objective: In this study we aimed to assess the usability and effectiveness of the MotherHeat Alert in the Tshwane District, South Africa. OBJECTIVE In this study we aimed to assess the usability and effectiveness of the MotherHeat Alert in the Tshwane District, South Africa. METHODS This prospective observational evaluation study included a cohort of 201 participants (100 pregnant, 101 postpartum) which were followed over a six-month period. In addition, a questionnaire was administered at three time points; baseline, midline and endline, to collect self-reported information on health, living situation, heat exposure, amongst other parameters. Usability was evaluated in the endline questionnaire through a validated Post-Study System Usability Questionnaire (PSSUQ), using descriptive statistics. Effectiveness was assessed through changes in self-reported heat-protective behaviours between baseline, midline and endline, as well as through endline assessments of heat-health knowledge increase and self-reported behaviour change attributable to the intervention. Generalised estimating equations were used to analyse repeated measures of heat-protective behaviours, while descriptive statistics were used to summarise endline-reported knowledge gains and behaviour change. RESULTS Usability scores indicated high overall usability, with mean PSSUQ scores of 1.76 (SD=0.60) among pregnant women and 1.37 (SD=0.45) among postpartum women. Similar patterns were observed across most PSSUQ subscales, including system usefulness, interface quality and information quality. Most self-reported behaviour change due to alerts received through the app was rated as large to very large by the pregnant women (67.2%) and postpartum women (82.9%). Nevertheless, comparing behaviour change at baseline and endline mainly highlighted a decrease in protective behaviour in both pregnant and postpartum cohorts. Self-reported knowledge increase among pregnant and postpartum women was reported as large to very large following the use of the EWS (79% and 88%, respectively). CONCLUSIONS The MotherHeat Alert application demonstrated positive outcomes in usability. Effectiveness showed conflicting results, with positive self-reports on behaviour change and knowledge increase, yet a decrease in protective heat behaviours when comparing baseline and midline with endline results, likely due to seasonality effects. Nevertheless, these findings highlight the potential of tailored EWS to support heat adaptation among pregnant and postpartum populations. Successful implementation and scalability require careful consideration of contextual factors, further assessment of long-term usability and integration into existing health infrastructure. CLINICALTRIAL The study was registered with the South African National Clinical Trial Registry (DOH-27-032025-5623), as part of the EU and UK-funded High Horizons project.
- Open Access
- 24 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Implementing wearable electronic devices to measure physiological effects of heat on pregnant women in Tshwane, South Africa: Lessons from the field (Preprint)
BACKGROUND There is limited individual-level personalised data measuring the effect of heat exposure on health outcomes. While technologies that provide individual-level continuous, physiological, and behavioural metrics are increasingly available, their use in low- and middle-income countries (LMICs) remains limited, where the implementation of mHealth and wearable devices faces unique challenges. OBJECTIVE To describe experiences from implementing wearable devices to track heat exposure and key physiological parameters among pregnant and postpartum women in Tshwane, South Africa. METHODS Pregnant women (gestational age 30-36 weeks) were enrolled and trained on the use of a wearable Fitbit Inspire 3 activity tracking device worn on their wrist, with an iButton temperature monitor attached. Women were asked to wear the device daily, from enrolment up to six weeks postpartum; with data downloads every 4-6 days. The devices collected data periodically on ambient temperature, sleep, physical activity and heart rate. At study exit, women completed questionnaires about their experiences with the wearables. RESULTS Of 25 women enrolled, 64% lived in informal dwellings, 92% had iron sheet roofing, and 35% lacked access to electricity, necessitating frequent home visits by study staff to provide wearable charging via power banks. Internal storage on the FitBit device was limited to 7-days so data downloads were required every 4-6 days. Among 22 women who completed the study, time wearing the device for over four hours per day accounted for 37.0% overall during the study period but varied considerably between participants. Women reported feeling unsafe wearing the device (24%) and forgetting or not wearing it while doing daily chores (15%). Wear-time improved after engagement to encourage and support more regular use of the devices through additional counselling during study visits to download the data. Women reported the wearables increased awareness of their activity levels, motivating them be more active. CONCLUSIONS The study describes our experiences with wearable devices use among pregnant women predominantly living in informal settlements with limited access to basic services and poor dwelling infrastructure. The influence of access to physiological parameters and its impact on personal activity has not been previously reported in this population. Despite high cellphone penetration, which can facilitate the use of mHealth technologies, significant implementation challenges remain in terms of access to smartphones to sync data, electricity supply, user safety concerns, and data completeness.
- 24 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImplementing wearable electronic devices to measure physiological effects of heat on pregnant women in Tshwane, South Africa: Lessons from the field (Preprint)
BACKGROUND There is limited individual-level personalised data measuring the effect of heat exposure on health outcomes. While technologies that provide individual-level continuous, physiological, and behavioural metrics are increasingly available, their use in low- and middle-income countries (LMICs) remains limited, where the implementation of mHealth and wearable devices faces unique challenges. OBJECTIVE To describe experiences from implementing wearable devices to track heat exposure and key physiological parameters among pregnant and postpartum women in Tshwane, South Africa. METHODS Pregnant women (gestational age 30-36 weeks) were enrolled and trained on the use of a wearable Fitbit Inspire 3 activity tracking device worn on their wrist, with an iButton temperature monitor attached. Women were asked to wear the device daily, from enrolment up to six weeks postpartum; with data downloads every 4-6 days. The devices collected data periodically on ambient temperature, sleep, physical activity and heart rate. At study exit, women completed questionnaires about their experiences with the wearables. RESULTS Of 25 women enrolled, 64% lived in informal dwellings, 92% had iron sheet roofing, and 35% lacked access to electricity, necessitating frequent home visits by study staff to provide wearable charging via power banks. Internal storage on the FitBit device was limited to 7-days so data downloads were required every 4-6 days. Among 22 women who completed the study, time wearing the device for over four hours per day accounted for 37.0% overall during the study period but varied considerably between participants. Women reported feeling unsafe wearing the device (24%) and forgetting or not wearing it while doing daily chores (15%). Wear-time improved after engagement to encourage and support more regular use of the devices through additional counselling during study visits to download the data. Women reported the wearables increased awareness of their activity levels, motivating them be more active. CONCLUSIONS The study describes our experiences with wearable devices use among pregnant women predominantly living in informal settlements with limited access to basic services and poor dwelling infrastructure. The influence of access to physiological parameters and its impact on personal activity has not been previously reported in this population. Despite high cellphone penetration, which can facilitate the use of mHealth technologies, significant implementation challenges remain in terms of access to smartphones to sync data, electricity supply, user safety concerns, and data completeness.
- Open Access
- 2 September 2025
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 115 (8) , e3121
Clot twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
Background. Rapid COVID‐19 vaccine development occurred during the pandemic and vaccine‐related complications such as thrombosis with thrombocytopenia syndrome were discovered. Clinical trials and treating facilities included D‐dimer testing in COVID‐19 vaccine trials and COVID‐19 disease‐severity assessments, respectively. D‐dimer testing and result interpretation is complex and its use in isolation is controversial. Objectives. To evaluate D‐dimer levels in healthy adult participants regardless of HIV status, prior to and 2 weeks after receipt of fractional and full‐dose Ad26.COV2.S or Comirnaty booster COVID‐19 vaccination, after a full dose Ad26.COV2.S prime, stratified by booster vaccination arm, age and HIV status. Methods. BaSiS, a prospective open‐label trial, enrolled 289 healthy adults. Participants with controlled comorbidities, HIV infection with no immunological or virological exclusions, and no prior thrombosis enrolled at four sites in South Africa (SA). Participants previously received a single Ad26.COV2.S prime vaccination through the Sisonke phase IIIB open‐label implementation study or the COVID‐19 vaccine programme in SA. Participants were randomised 1:1:1:1 to receive one of four boosters: full‐dose Ad26.COV2.S, half‐dose Ad26.COV2.S, full‐dose Comirnaty or half‐dose Comirnaty. D‐dimer testing (INNOVANCE D‐dimer assay), as a coagulopathy marker, was conducted before the booster (baseline) and 2 weeks after the booster. The primary objectives previously reported included safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or Comirnaty in Ad26.COV2.S‐vaccinated participants. An exploratory objective evaluating clotting profiles, measured by D‐dimers, is reported here. Results. The median age among 285 evaluable participants included in this analysis was 42.2 (interquartile range (IQR): 35.5 ‐ 48.7) years; 82.5% (235/285) were female and 94.4% (269/285) were black African. Of the 40.4% (115/285) of people living with HIV, 79.1% (91/115) were well controlled on antiretroviral therapy. At baseline, 39.3% (112/285) of participants had elevated D‐dimer levels ‒ all asymptomatic. Females and obese participants were significantly more likely to have elevated baseline D‐dimer levels (adjusted odds ratio (aOR): 3.14, 95% confidence interval (CI): 1.32 ‐ 7.48 and aOR: 2.20, 95% CI: 1.22 ‐ 3.96, respectively). Of 276 participants with D‐dimer results available at 2 weeks after the booster, 109 (39.5%) had elevated D‐dimer levels. Those with elevated levels at baseline and female participants (aOR: 14.75, 95% CI: 7.64 ‐ 28.48 and aOR: 3.24, 95% CI: 1.14 ‐ 9.22, respectively) were significantly more likely to have elevated D‐dimer levels at 2 weeks. Conclusion. Elevated D‐dimer levels in asymptomatic, low‐risk adults were unexpectedly common and not associated with thromboembolism. This supports the rationale of including D‐dimer testing in conjunction with other coagulopathy markers, only if clinically indicated in both COVID‐19 vaccine clinical trials and the general population.
- 2 September 2025
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 115 (8) , e3121
Open AccessClot twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
Background. Rapid COVID‐19 vaccine development occurred during the pandemic and vaccine‐related complications such as thrombosis with thrombocytopenia syndrome were discovered. Clinical trials and treating facilities included D‐dimer testing in COVID‐19 vaccine trials and COVID‐19 disease‐severity assessments, respectively. D‐dimer testing and result interpretation is complex and its use in isolation is controversial. Objectives. To evaluate D‐dimer levels in healthy adult participants regardless of HIV status, prior to and 2 weeks after receipt of fractional and full‐dose Ad26.COV2.S or Comirnaty booster COVID‐19 vaccination, after a full dose Ad26.COV2.S prime, stratified by booster vaccination arm, age and HIV status. Methods. BaSiS, a prospective open‐label trial, enrolled 289 healthy adults. Participants with controlled comorbidities, HIV infection with no immunological or virological exclusions, and no prior thrombosis enrolled at four sites in South Africa (SA). Participants previously received a single Ad26.COV2.S prime vaccination through the Sisonke phase IIIB open‐label implementation study or the COVID‐19 vaccine programme in SA. Participants were randomised 1:1:1:1 to receive one of four boosters: full‐dose Ad26.COV2.S, half‐dose Ad26.COV2.S, full‐dose Comirnaty or half‐dose Comirnaty. D‐dimer testing (INNOVANCE D‐dimer assay), as a coagulopathy marker, was conducted before the booster (baseline) and 2 weeks after the booster. The primary objectives previously reported included safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or Comirnaty in Ad26.COV2.S‐vaccinated participants. An exploratory objective evaluating clotting profiles, measured by D‐dimers, is reported here. Results. The median age among 285 evaluable participants included in this analysis was 42.2 (interquartile range (IQR): 35.5 ‐ 48.7) years; 82.5% (235/285) were female and 94.4% (269/285) were black African. Of the 40.4% (115/285) of people living with HIV, 79.1% (91/115) were well controlled on antiretroviral therapy. At baseline, 39.3% (112/285) of participants had elevated D‐dimer levels ‒ all asymptomatic. Females and obese participants were significantly more likely to have elevated baseline D‐dimer levels (adjusted odds ratio (aOR): 3.14, 95% confidence interval (CI): 1.32 ‐ 7.48 and aOR: 2.20, 95% CI: 1.22 ‐ 3.96, respectively). Of 276 participants with D‐dimer results available at 2 weeks after the booster, 109 (39.5%) had elevated D‐dimer levels. Those with elevated levels at baseline and female participants (aOR: 14.75, 95% CI: 7.64 ‐ 28.48 and aOR: 3.24, 95% CI: 1.14 ‐ 9.22, respectively) were significantly more likely to have elevated D‐dimer levels at 2 weeks. Conclusion. Elevated D‐dimer levels in asymptomatic, low‐risk adults were unexpectedly common and not associated with thromboembolism. This supports the rationale of including D‐dimer testing in conjunction with other coagulopathy markers, only if clinically indicated in both COVID‐19 vaccine clinical trials and the general population.
- 14 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (2S) , S85-S89
Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective
Background: Maternal immunization is a valuable public health measure protecting the mother, fetus and newborn infant against targeted infectious diseases, playing an integral role in pregnancy outcomes. Limited literature exists from the African continent pertaining to the timing and utilization of maternal influenza and tetanus toxoid immunization. Maintaining high vaccine coverage is imperative for successful disease control, highlighting the importance of continued maternal immunization. We aimed to describe the utilization and timing of influenza and tetanus vaccinations during pregnancy, within South African publicly financed antenatal care facilities. Methods: A secondary analysis was conducted of clinical antenatal, vaccination and delivery data collected during a retrospective review of randomly selected maternity charts of women who delivered between July 2018 and June 2019 in Johannesburg and Cape Town, South Africa. Results: Influenza vaccination uptake within the sampled population was 16.6% (806/4851), with significantly higher odds of influenza vaccination in women 21-30 years of age and women with ≥6 antenatal care visits. Of 7031 (99.0% of the population) women who received at least 1 dose of tetanus toxoid–containing vaccine (TTCV), 39.2% (2759) received 1 dose; 51.0% (3590) received 2 and 9.7% (682) received 3 doses in their index pregnancy. Conculsions: Antenatal facilities are ideally suited to administer vaccines to pregnant women; however, targeted educational campaigns and immunization promotion by antenatal staff will improve maternal influenza immunization coverage. There is high utilization of TTCV in South Africa, with over 99% of women receiving at least 1 dose of TTCV, which is encouraging, especially considering that South Africa is implementing a single dose of a combination tetanus-diphtheria-acellular pertussis vaccine to replace tetanus toxoid (TT) in pregnancy.
- 14 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (2S) , S85-S89
Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective
Background: Maternal immunization is a valuable public health measure protecting the mother, fetus and newborn infant against targeted infectious diseases, playing an integral role in pregnancy outcomes. Limited literature exists from the African continent pertaining to the timing and utilization of maternal influenza and tetanus toxoid immunization. Maintaining high vaccine coverage is imperative for successful disease control, highlighting the importance of continued maternal immunization. We aimed to describe the utilization and timing of influenza and tetanus vaccinations during pregnancy, within South African publicly financed antenatal care facilities. Methods: A secondary analysis was conducted of clinical antenatal, vaccination and delivery data collected during a retrospective review of randomly selected maternity charts of women who delivered between July 2018 and June 2019 in Johannesburg and Cape Town, South Africa. Results: Influenza vaccination uptake within the sampled population was 16.6% (806/4851), with significantly higher odds of influenza vaccination in women 21-30 years of age and women with ≥6 antenatal care visits. Of 7031 (99.0% of the population) women who received at least 1 dose of tetanus toxoid–containing vaccine (TTCV), 39.2% (2759) received 1 dose; 51.0% (3590) received 2 and 9.7% (682) received 3 doses in their index pregnancy. Conculsions: Antenatal facilities are ideally suited to administer vaccines to pregnant women; however, targeted educational campaigns and immunization promotion by antenatal staff will improve maternal influenza immunization coverage. There is high utilization of TTCV in South Africa, with over 99% of women receiving at least 1 dose of TTCV, which is encouraging, especially considering that South Africa is implementing a single dose of a combination tetanus-diphtheria-acellular pertussis vaccine to replace tetanus toxoid (TT) in pregnancy.
- Open Access
- 26 November 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (12) , 1565
Scoping Review of Climate Change Adaptation Interventions for Health: Implications for Policy and Practice
Climate change is among the greatest threats to health in the 21st century, requiring the urgent scaling-up of adaptation interventions. We aim to summarise adaptation interventions that were funded by the Belmont Forum and the European Union, the largest global funders of climate change and health research. A systematic search was conducted (updated February 2023) to identify articles on adaptation interventions for health within this funding network. The data extracted included study characteristics, types of interventions, and study outcomes. The results were synthesised narratively within the PRISMA-ScR guidelines. A total of 197 articles were screened, with 37 reporting on adaptation interventions. The majority of interventions focused on the general population (n = 17), with few studies examining high-risk populations such as pregnant women and children (n = 4) or migrants (n = 0). Targeted interventions were mostly aimed at behavioural change (n = 8) and health system strengthening (n = 6), while interventions with mitigation co-benefits such as nature-based solutions (n = 1) or the built environment (n = 0) were limited. The most studied climate change hazard was extreme heat (n = 26). Several studies reported promising findings, principally regarding interventions to counter heat impacts on workers and pregnant women and improving risk awareness in communities. These findings provide a platform on which to expand research and public health interventions for safeguarding public health from the effects of climate change.
- 26 November 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (12) , 1565
Open AccessScoping Review of Climate Change Adaptation Interventions for Health: Implications for Policy and Practice
Climate change is among the greatest threats to health in the 21st century, requiring the urgent scaling-up of adaptation interventions. We aim to summarise adaptation interventions that were funded by the Belmont Forum and the European Union, the largest global funders of climate change and health research. A systematic search was conducted (updated February 2023) to identify articles on adaptation interventions for health within this funding network. The data extracted included study characteristics, types of interventions, and study outcomes. The results were synthesised narratively within the PRISMA-ScR guidelines. A total of 197 articles were screened, with 37 reporting on adaptation interventions. The majority of interventions focused on the general population (n = 17), with few studies examining high-risk populations such as pregnant women and children (n = 4) or migrants (n = 0). Targeted interventions were mostly aimed at behavioural change (n = 8) and health system strengthening (n = 6), while interventions with mitigation co-benefits such as nature-based solutions (n = 1) or the built environment (n = 0) were limited. The most studied climate change hazard was extreme heat (n = 26). Several studies reported promising findings, principally regarding interventions to counter heat impacts on workers and pregnant women and improving risk awareness in communities. These findings provide a platform on which to expand research and public health interventions for safeguarding public health from the effects of climate change.
- Open Access
- 7 November 2024
- Published by MDPI AG in Preprints.org
Scoping Review of Climate Change Adaptation Interventions for Health: Implications for Policy and Practice
Climate Change is among the greatest threats to health in the 21st century, requiring urgent scale-up of adaptation interventions. We aim to summarize adaptation interventions that were funded by the Belmont Forum and the European Union, the largest global funders of climate change and health research. A systematic search was conducted (updated February 2023) to identify articles on adaptation interventions for health within this funding network. Data extracted included study characteristics, types of interventions, and study outcomes. Results were synthesised narratively within the PRISMA-ScR guidelines. 197 articles were screened, with 37 reporting on adaptation interventions. The majority of interventions focused on the general population (n=17), with few studies examining high-risk populations such as pregnant women and children (n=4) or migrants (n=0). Targeted interventions were mostly aimed at behaviour change (n=8) and health system strengthening (n=6), while interventions with mitigation co-benefits such as nature-based solutions (n=1) or the built environment (n=0) were limited. The most studied climate change hazard was extreme heat (n=26). Several studies reported promising findings, principally on interventions to counter heat impacts in workers and pregnant women, and improving risk awareness in communities. These findings provide a platform on which to expand research and public health interventions towards safeguarding public health from the effects of climate change.
- 7 November 2024
- Published by MDPI AG in Preprints.org
Open AccessScoping Review of Climate Change Adaptation Interventions for Health: Implications for Policy and Practice
Climate Change is among the greatest threats to health in the 21st century, requiring urgent scale-up of adaptation interventions. We aim to summarize adaptation interventions that were funded by the Belmont Forum and the European Union, the largest global funders of climate change and health research. A systematic search was conducted (updated February 2023) to identify articles on adaptation interventions for health within this funding network. Data extracted included study characteristics, types of interventions, and study outcomes. Results were synthesised narratively within the PRISMA-ScR guidelines. 197 articles were screened, with 37 reporting on adaptation interventions. The majority of interventions focused on the general population (n=17), with few studies examining high-risk populations such as pregnant women and children (n=4) or migrants (n=0). Targeted interventions were mostly aimed at behaviour change (n=8) and health system strengthening (n=6), while interventions with mitigation co-benefits such as nature-based solutions (n=1) or the built environment (n=0) were limited. The most studied climate change hazard was extreme heat (n=26). Several studies reported promising findings, principally on interventions to counter heat impacts in workers and pregnant women, and improving risk awareness in communities. These findings provide a platform on which to expand research and public health interventions towards safeguarding public health from the effects of climate change.
- Open Access
- 11 April 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (4) , e0002703
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated. No vaccine-associated serious adverse events were recorded. The full- and half-dose BNT162b2 boosted anti-SARS-CoV-2 binding antibody levels (3.9- and 4.5-fold, respectively) and neutralizing antibody levels (4.4- and 10-fold). Binding and neutralizing antibodies following half-dose Ad26.COV2.S were not significantly boosted. Full-dose Ad26.COV2.S did not boost binding antibodies but slightly enhanced neutralizing antibodies (2.1-fold). ADCC was marginally increased only after a full-dose BNT162b2. T-cell responses followed a similar pattern to neutralizing antibodies. Six months post-boost, antibody and T-cell responses had waned to baseline levels. While we detected strong anti-vector immunity, there was no correlation between anti-vector immunity in Ad26.COV2.S recipients and spike-specific neutralizing antibody or T-cell responses post-Ad26.COV2.S boosting. Overall, in the context of hybrid immunity, boosting with heterologous full- or half-dose BNT162b2 mRNA vaccine demonstrated superior immunogenicity 2 weeks post-vaccination compared to homologous Ad26.COV2.S, though rapid waning occurred by 12 weeks post-boost. Trial Registration: The study has been registered to the South African National Clinical Trial Registry (SANCTR): DOH-27-012022-7841. The approval letter from SANCTR has been provided in the up-loaded documents.
- 11 April 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (4) , e0002703
Open AccessSafety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated. No vaccine-associated serious adverse events were recorded. The full- and half-dose BNT162b2 boosted anti-SARS-CoV-2 binding antibody levels (3.9- and 4.5-fold, respectively) and neutralizing antibody levels (4.4- and 10-fold). Binding and neutralizing antibodies following half-dose Ad26.COV2.S were not significantly boosted. Full-dose Ad26.COV2.S did not boost binding antibodies but slightly enhanced neutralizing antibodies (2.1-fold). ADCC was marginally increased only after a full-dose BNT162b2. T-cell responses followed a similar pattern to neutralizing antibodies. Six months post-boost, antibody and T-cell responses had waned to baseline levels. While we detected strong anti-vector immunity, there was no correlation between anti-vector immunity in Ad26.COV2.S recipients and spike-specific neutralizing antibody or T-cell responses post-Ad26.COV2.S boosting. Overall, in the context of hybrid immunity, boosting with heterologous full- or half-dose BNT162b2 mRNA vaccine demonstrated superior immunogenicity 2 weeks post-vaccination compared to homologous Ad26.COV2.S, though rapid waning occurred by 12 weeks post-boost. Trial Registration: The study has been registered to the South African National Clinical Trial Registry (SANCTR): DOH-27-012022-7841. The approval letter from SANCTR has been provided in the up-loaded documents.
- Open Access
- 22 March 2024
- Published by Wiley in HIV Medicine
- Vol. 25 (7) , 826-839
Assessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study
Introduction: Although dolutegravir (DTG) is deemed stable, safe, cost‐effective, and clinically beneficial, it also carries the risk of side effects, including observed weight gain among patients on DTG‐based antiretroviral therapy (ART) regimens. We compared weight changes among adults (≥18 years) initiating tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) or tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE) regimens and those switching from TEE to TLD (TEE‐to‐TLD switchers) in three large primary care facilities in South AfricaMethods: We conducted a retrospective longitudinal record review using patient medical records, extracting relevant demographic and clinical data from October 2018 to June 2021 from randomly selected adults who initiated TLD or TEE (initiators) and adult TEE‐to‐TLD switchers. We assessed weight, body mass index (BMI), and percentage weight changes for both groups and fitted linear regression and generalized linear models to determine factors associated with weight and BMI change and percentage weight change ≥10%, respectively, among treatment initiators. We fitted linear mixed‐effect models among TEE‐to‐TLD switchers to consider repeated measures.Results: Of 860 initiators, 450 (52.3%) initiated on TEE and 410 (47.7%) on TLD, with median follow‐up of 1.4 years and 1.0 year, respectively. At initiation, 43.3% on TEE and 40.8% on TLD were overweight or obese. TLD initiators had an adjusted higher mean weight gain of 1.6 kg (p < 0.001) and mean BMI gain of 0.51 kg/m2 (p < 0.001) than TEE initiators. Independent risk factors for higher mean weight and BMI included age ≥50 years, male, on ART for >12 months, initial BMI of 2, and CD4 counts p = 0.026). Being overweight and CD4 counts >350 cells/μL were independent risk factors for lower weight gain after TLD switch.Conclusions: We report more weight gain among TLD than among TEE initiators, although to a lesser extent than previously reported. TEE‐to‐TLD switchers experienced less weight gain after TLD switch; return to health before receiving TLD may be a contributory factor. The current findings are reassuring for those switching to a DTG‐based regimen
- 22 March 2024
- Published by Wiley in HIV Medicine
- Vol. 25 (7) , 826-839
Open AccessAssessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study
Introduction: Although dolutegravir (DTG) is deemed stable, safe, cost‐effective, and clinically beneficial, it also carries the risk of side effects, including observed weight gain among patients on DTG‐based antiretroviral therapy (ART) regimens. We compared weight changes among adults (≥18 years) initiating tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) or tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE) regimens and those switching from TEE to TLD (TEE‐to‐TLD switchers) in three large primary care facilities in South AfricaMethods: We conducted a retrospective longitudinal record review using patient medical records, extracting relevant demographic and clinical data from October 2018 to June 2021 from randomly selected adults who initiated TLD or TEE (initiators) and adult TEE‐to‐TLD switchers. We assessed weight, body mass index (BMI), and percentage weight changes for both groups and fitted linear regression and generalized linear models to determine factors associated with weight and BMI change and percentage weight change ≥10%, respectively, among treatment initiators. We fitted linear mixed‐effect models among TEE‐to‐TLD switchers to consider repeated measures.Results: Of 860 initiators, 450 (52.3%) initiated on TEE and 410 (47.7%) on TLD, with median follow‐up of 1.4 years and 1.0 year, respectively. At initiation, 43.3% on TEE and 40.8% on TLD were overweight or obese. TLD initiators had an adjusted higher mean weight gain of 1.6 kg (p < 0.001) and mean BMI gain of 0.51 kg/m2 (p < 0.001) than TEE initiators. Independent risk factors for higher mean weight and BMI included age ≥50 years, male, on ART for >12 months, initial BMI of 2, and CD4 counts p = 0.026). Being overweight and CD4 counts >350 cells/μL were independent risk factors for lower weight gain after TLD switch.Conclusions: We report more weight gain among TLD than among TEE initiators, although to a lesser extent than previously reported. TEE‐to‐TLD switchers experienced less weight gain after TLD switch; return to health before receiving TLD may be a contributory factor. The current findings are reassuring for those switching to a DTG‐based regimen
- Open Access
Clot Twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
BaSiS ( B ooster A fter Si sonke S tudy) is a prospectively enrolled open-label trial in which healthy adults, with controlled co-morbidities and no prior thrombosis, who received a single Ad26.COV2.S prime vaccination primarily through the Sisonke phase IIIB open label implementation study in South Africa. An exploratory objective evaluated the clotting profiles of participants who were enrolled across 4 sites in South Africa and randomised 1:1:1:1 to receive one of full-dose Ad26.COV2.S, half-dose Ad26.COV2.S, full-dose Comirnaty or half-dose Comirnaty booster. D-dimer testing (INNOVANCE®D-Dimer Assay), as a coagulopathy marker, was conducted pre-booster (baseline) and 2 weeks post-booster. The median age among 285 participants was 42.2 years (IQR:35.5-48.7), 235/285 (82.5%) were female, 269/285 (94.4%) were Black African. Of the 40.4% (115/285) people living with HIV (PLHIV), 79.1% (91/115) were well-controlled on antiretroviral therapy. At baseline, 39.3% (112/285) had elevated d-dimers; all asymptomatic. Females and obese participants were significantly more likely to have elevated baseline d-dimers (OR=4.17; 95% CI:1.88 to 9.26 and OR=2.64; 95% CI:1.57 to 4.43, respectively). Of 169 with normal baseline d-dimers, 29 (17.2%) became elevated 2 weeks post-booster: median increase 0.23µg/ml (IQR:0.15-0.42); those receiving full-dose Comirnaty exhibited lower risk of d-dimer elevation post vaccination, compared to other booster vaccination arms (OR:0.26; 95% CI:0.07 to 0.98). PLHIV experienced significantly higher median increases compared to HIV uninfected participants (0.43 vs 0.17, p=0.004). Elevated d-dimers in asymptomatic, low-risk adults were unexpectedly common but were not associated with thromboembolism, supporting the rationale of using d-dimers only if clinically indicated. Trial Registration: South African Clinical Trails Register number DOH-27-012022-7841.
Open AccessClot Twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
BaSiS ( B ooster A fter Si sonke S tudy) is a prospectively enrolled open-label trial in which healthy adults, with controlled co-morbidities and no prior thrombosis, who received a single Ad26.COV2.S prime vaccination primarily through the Sisonke phase IIIB open label implementation study in South Africa. An exploratory objective evaluated the clotting profiles of participants who were enrolled across 4 sites in South Africa and randomised 1:1:1:1 to receive one of full-dose Ad26.COV2.S, half-dose Ad26.COV2.S, full-dose Comirnaty or half-dose Comirnaty booster. D-dimer testing (INNOVANCE®D-Dimer Assay), as a coagulopathy marker, was conducted pre-booster (baseline) and 2 weeks post-booster. The median age among 285 participants was 42.2 years (IQR:35.5-48.7), 235/285 (82.5%) were female, 269/285 (94.4%) were Black African. Of the 40.4% (115/285) people living with HIV (PLHIV), 79.1% (91/115) were well-controlled on antiretroviral therapy. At baseline, 39.3% (112/285) had elevated d-dimers; all asymptomatic. Females and obese participants were significantly more likely to have elevated baseline d-dimers (OR=4.17; 95% CI:1.88 to 9.26 and OR=2.64; 95% CI:1.57 to 4.43, respectively). Of 169 with normal baseline d-dimers, 29 (17.2%) became elevated 2 weeks post-booster: median increase 0.23µg/ml (IQR:0.15-0.42); those receiving full-dose Comirnaty exhibited lower risk of d-dimer elevation post vaccination, compared to other booster vaccination arms (OR:0.26; 95% CI:0.07 to 0.98). PLHIV experienced significantly higher median increases compared to HIV uninfected participants (0.43 vs 0.17, p=0.004). Elevated d-dimers in asymptomatic, low-risk adults were unexpectedly common but were not associated with thromboembolism, supporting the rationale of using d-dimers only if clinically indicated. Trial Registration: South African Clinical Trails Register number DOH-27-012022-7841.